Surgery Websites
Tolani Lab »  Publications


View by Year:
Tolani B, Hoang NT, Acevedo LA, Leprieur EG, Li H, He B, Jablons DM
Preclinical characterization of therapeutic antibodies targeted at the carboxy-terminus of Sonic hedgehog.
Oncotarget, Mar-06-2018;[epublish]9(18):14311-14323.
Tolani B, Acevedo LA, Hoang NT, He B
Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
International journal of molecular sciences, Jan-13-2018;[epublish]19(1):.
Hoang NT, Acevedo LA, Mann MJ, Tolani B
A review of soft-tissue sarcomas: translation of biological advances into treatment measures.
Cancer management and research, 2018;[epublish]10:1089-1114.
Leprieur EG, Tolani B, Li H, Leguay F, Hoang NT, Acevedo LA, Jin JQ, Tseng HH, Yue D, Kim IJ, Wislez M, Wang C, Jablons DM, He B
Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer.
Oncotarget, Nov-28-2017;[epublish]8(61):103744-103757.
Chang Y, Tolani B, Nie X, Zhi X, Hu M, He B
Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring.
Therapeutics and clinical risk management, 2017;[epublish]13:1363-1374.
Li H, Yue D, Jin JQ, Woodard GA, Tolani B, Luh TM, Giroux-Leprieur E, Mo M, Chen Z, Che J, Zhang Z, Zhou Y, Wang L, Hao X, Jablons D, Wang C, He B
Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas.
Oncotarget, Aug-12-2016;[Epub ahead of print].
Gopalakrishnan R, Matta H, Tolani B, Triche T, Chaudhary PM
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Oncogene, Apr-7-2016;35(14):1797-810.  Epub 2015 Jun 29.
Mo ML, Ma J, Chen Z, Wei B, Li H, Zhou Y, Shi H, Tolani B, Jin JQ, Tseng HH, Shen D, Zhan Y, Li J, Jablons DM, Zhang RQ, Guo Y, He B, Zhou HM
Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer.
Journal of cancer research and clinical oncology, May-2015;141(5):901-8.  Epub 2014 Nov 4.
Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas.
PloS one, 2015;[epublish]10(7):e0132134.
Tolani B, Matta H, Gopalakrishnan R, Punj V, Chaudhary PM
NEMO is essential for Kaposi's sarcoma-associated herpesvirus-encoded vFLIP K13-induced gene expression and protection against death receptor-induced cell death, and its N-terminal 251 residues are sufficient for this process.
Journal of virology, Jun-2014;88(11):6345-54.  Epub 2014 Mar 26.
Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM
Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
Oncogene, May-29-2014;33(22):2928-37.  Epub 2013 Jun 24.
Graham C, Matta H, Yang Y, Yi H, Suo Y, Tolani B, Chaudhary PM
Kaposi's sarcoma-associated herpesvirus oncoprotein K13 protects against B cell receptor-induced growth arrest and apoptosis through NF-κB activation.
Journal of virology, Feb-2013;87(4):2242-52.  Epub 2012 Dec 12.
Matta H, Gopalakrishnan R, Graham C, Tolani B, Khanna A, Yi H, Suo Y, Chaudhary PM
Kaposi's sarcoma associated herpesvirus encoded viral FLICE inhibitory protein K13 activates NF-κB pathway independent of TRAF6, TAK1 and LUBAC.
PloS one, 2012;7(5):e36601.